WF Holding Announces Pricing of Initial Public Offering
Company to list shares on Nasdaq Capital Market under symbol “WFF” KUALA LUMPUR, March 26, 2025 (GLOBE NEWSWIRE) — WF […]
Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva
PALO ALTO, Calif., March 26, 2025 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating […]
Ryoncil® is Now Available for Purchase in the United States
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory […]
LeddarTech Reports Annual Shareholder Meeting Results
QUEBEC CITY, Canada, March 26, 2025 (GLOBE NEWSWIRE) — LeddarTech® Holdings Inc. (“LeddarTech” or the “Corporation”) (Nasdaq: LDTC), an automotive […]
23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law
SAN FRANCISCO, March 26, 2025 (GLOBE NEWSWIRE) — 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME), a leading human […]
Prairie Operating Co. Completes Transformative Acquisition from Bayswater
Expands footprint in DJ Basin to ~55,000 net acres and inventory life to ~10 years Increases average daily production by […]
Alvotech Reports Record Results for 2024 and Provides Business Update
Total Revenues in 2024 reached $492 million, representing a 427% increase over prior year Product Revenues in 2024 reached $273 […]
Soleno Therapeutics Announces U.S. FDA Approval of VYKAT(TM) XR to Treat Hyperphagia in Prader-Willi Syndrome
First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March […]
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – March 26, 2025 – 10:05 […]
Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved
In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025$17.5 million increase in Working Capital; Cash […]
